Cingulate (CING) Competitors $3.78 -0.05 (-1.33%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. ABOS, STRO, OKYO, RPTX, CRVO, QNTM, VTVT, ARTV, UNCY, and OSTXShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Acumen Pharmaceuticals (ABOS), Sutro Biopharma (STRO), OKYO Pharma (OKYO), Repare Therapeutics (RPTX), CervoMed (CRVO), Quantum Biopharma (QNTM), vTv Therapeutics (VTVT), Artiva Biotherapeutics (ARTV), Unicycive Therapeutics (UNCY), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Its Competitors Acumen Pharmaceuticals Sutro Biopharma OKYO Pharma Repare Therapeutics CervoMed Quantum Biopharma vTv Therapeutics Artiva Biotherapeutics Unicycive Therapeutics OS Therapies Cingulate (NASDAQ:CING) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Does the media refer more to CING or ABOS? In the previous week, Cingulate had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Cingulate and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.91 beat Cingulate's score of 0.48 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Cingulate Neutral Acumen Pharmaceuticals Very Positive Which has higher valuation & earnings, CING or ABOS? Cingulate is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$15.55M-$4.10-0.92Acumen PharmaceuticalsN/AN/A-$102.33M-$2.28-0.67 Is CING or ABOS more profitable? Acumen Pharmaceuticals' return on equity of -81.39% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -232.16% -132.07% Acumen Pharmaceuticals N/A -81.39%-61.96% Do analysts rate CING or ABOS? Cingulate presently has a consensus price target of $26.25, suggesting a potential upside of 594.63%. Acumen Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 357.52%. Given Cingulate's higher possible upside, equities analysts plainly believe Cingulate is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, CING or ABOS? Cingulate has a beta of -0.76, meaning that its share price is 176% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Do institutionals and insiders have more ownership in CING or ABOS? 41.3% of Cingulate shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 4.0% of Cingulate shares are owned by company insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAcumen Pharmaceuticals beats Cingulate on 8 of the 12 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulateMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.40M$3.07B$5.65B$10.26BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-0.9220.6875.7026.05Price / SalesN/A397.57514.05168.79Price / CashN/A45.9137.5661.52Price / Book1.639.6212.876.29Net Income-$15.55M-$52.73M$3.29B$270.94M7 Day Performance7.36%0.59%-0.33%-0.30%1 Month Performance-10.02%6.27%3.77%6.20%1 Year Performance-26.62%18.55%68.18%28.32% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.4599 of 5 stars$3.78-1.3%$26.25+594.6%-23.6%$20.40MN/A-0.9220Analyst RevisionGap DownABOSAcumen Pharmaceuticals3.0484 of 5 stars$1.28+1.6%$7.00+446.9%-48.0%$76.32MN/A-0.5620Positive NewsGap UpSTROSutro Biopharma4.0357 of 5 stars$0.89+0.4%$4.47+401.8%-74.2%$75.16M$62.04M-0.35240Positive NewsGap DownOKYOOKYO Pharma2.2574 of 5 stars$2.25+13.6%$7.00+211.1%+108.9%$74.47MN/A0.007News CoveragePositive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeRPTXRepare Therapeutics3.1168 of 5 stars$1.72+0.6%$4.50+161.6%-48.8%$73.46M$53.48M-0.67180News CoverageCRVOCervoMed3.7187 of 5 stars$8.16+4.7%$19.29+136.3%-46.6%$72.08M$9.74M-3.134Positive NewsGap UpQNTMQuantum Biopharma0.4884 of 5 stars$18.49-2.0%N/A+338.1%$72MN/A-1.32N/ANews CoverageVTVTvTv Therapeutics2.3787 of 5 stars$22.44+0.2%$35.50+58.2%+69.0%$71.49M$1.02M-7.199Positive NewsGap UpARTVArtiva Biotherapeutics3.2418 of 5 stars$2.70-6.3%$17.00+529.6%-77.5%$70.35M$250K0.0081Positive NewsUNCYUnicycive Therapeutics2.4767 of 5 stars$3.96flat$57.00+1,339.4%-12.0%$69.94M$680K-0.969OSTXOS Therapies1.6956 of 5 stars$2.21+4.2%$18.00+714.5%-31.7%$69.94MN/A-2.80N/A Related Companies and Tools Related Companies Acumen Pharmaceuticals Competitors Sutro Biopharma Competitors OKYO Pharma Competitors Repare Therapeutics Competitors CervoMed Competitors Quantum Biopharma Competitors vTv Therapeutics Competitors Artiva Biotherapeutics Competitors Unicycive Therapeutics Competitors OS Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CING Stock Alerts